BCIQ Profiles

Company Profile ReportTarget Profile Report
0618 accelerated approval endpoints
BioCentury & Getty Images

Regulation 

Amyloid stands out among surrogate endpoints, and not in a good way: Data Byte

An analysis of five years of surrogate endpoints in accelerated approvals

An analysis of five years of surrogate endpoints in accelerated approvals reveals amyloid clearance has the weakest link to clinical benefit.

Jun 19, 2021 | 2:09 AM GMT

Among the 15 surrogate endpoints upon which FDA

Read the full 659 word article

How to gain access

Continue reading with a
two-week free trial.